Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort.
Frantzi N, Nguyen XP, Herr C, Alter P, Söhler S, Soriano D, Watz H, Waschki B, Trinkmann F, Eichenlaub M, Trudzinski FC, Michels-Zetsche JD, Omlor A, Seiler F, Moneke I, Biertz F, Rohde G, Stolz D, Welte T, Kauczor HU, Kahnert K, Jörres RA, Vogelmeier CF, Bals R, Fähndrich S; German COSYCONET Cohort. Frantzi N, et al. Respir Res. 2024 May 15;25(1):207. doi: 10.1186/s12931-024-02822-1. Respir Res. 2024. PMID: 38750572 Free PMC article.
Midregional proatrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all-cause mortality in recently diagnosed mild to moderate COPD-results from COSYCONET.
Fähndrich S, Herr C, Teuteberg S, Alter P, Söhler S, Soriano D, Classen J, Adams J, Weinhold V, Watz H, Waschki B, Zeller T, Eichenlaub M, Trudzinski FC, Michels JD, Omlor A, Seiler F, Moneke I, Biertz F, Stolz D, Welte T, Kauczor HU, Kahnert K, Jörres RA, Vogelmeier CF, Bals R; German COSYCONET Cohort. Fähndrich S, et al. Respir Res. 2024 Jan 24;25(1):56. doi: 10.1186/s12931-024-02690-9. Respir Res. 2024. PMID: 38267944 Free PMC article.
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.
Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, Olinger L, Cohen D, Menzies-Gow A, Korn S; SHAMAL Investigators. Jackson DJ, et al. Lancet. 2024 Jan 20;403(10423):271-281. doi: 10.1016/S0140-6736(23)02284-5. Epub 2023 Dec 7. Lancet. 2024. PMID: 38071986 Free article. Clinical Trial.
[Correction: Evaluating the reform of the psychotherapy guideline using a mixed-methods approach: a study protocol].
Diekmann S, Schlierenkamp S, Walendzik A, Abels C, Zur Nieden P, Best D, Schaff C, Timmermann H, Klipker K, Marschall U, Wasem J, Neusser S. Diekmann S, et al. Among authors: timmermann h. Gesundheitswesen. 2023 Nov;85(11):e48. doi: 10.1055/a-2167-0010. Epub 2023 Nov 16. Gesundheitswesen. 2023. PMID: 37972584 German. No abstract available.
43 results